Dezhan Healthcare Co Ltd

Dezhan Healthcare's capital structure is characterized by a high proportion of equity, with total equity of 4.64 billion CNY and total liabilities of 236.38 million CNY, resulting in a debt-to-equity ratio of 0.03. The company's liquidity position is mixed, with a current ratio of 16.48, but it has negative free cash flow of -567.84 million CNY and a negative operating income of -419.42 million CNY. The price-to-book ratio of 1.79 suggests the market values the company at a premium to its book value, but the negative return on equity of -7.45% and return on assets of -7.09% indicate poor profitability. The company's profitability is significantly below industry norms, with a net loss of 345.42 million CNY and an operating loss of 419.42 million CNY. The gross profit margin of 54.12% is relatively high, but the negative operating and net income suggest inefficiencies in cost management or revenue generation. The company's EBITDA multiple of -20.13 is not meaningful due to the negative EBITDA, and the EV-to-revenue ratio of 21.27 indicates a high valuation relative to its revenue. Dezhan Healthcare's revenue is concentrated in a single geographic market, primarily China, with no disclosed international operations. The company's revenue concentration in a single market increases its exposure to local economic and regulatory risks. The company's segments are not disclosed in detail, but the lack of diversification in revenue sources is a concern. The company's growth trajectory is negative, with a net loss and declining operating cash flow. The free cash flow is negative, and the capital expenditure of -235.99 million CNY indicates significant investment in operations. The company's outlook for the current fiscal year is negative, with no indication of improvement in the near term. The risk assessment indicates medium liquidity risk and low dilution risk, but the negative net cash position after subtracting total debt is a key flag. Recent events include a decline in earnings, with the last actual EPS of 0.15 CNY. The company's ESG score is low, with an overall score of 13.38 and a D grade, indicating poor environmental, social, and governance practices. The ESG controversies score of 100 suggests the company has faced significant controversies, which could impact its reputation and regulatory compliance.